Julie R. Gralow, MD: SWOG SO226 Trial and Bisphosphonates Update
Description: Dr. Julie R. Gralow discusses the SWOG SO226 where postmenopausal women with metastatic breast cancer given first-line treatment of fulvestrant (Faslodex) and anastrozole (Arimidix) have a better progression-free survival (PFS) than those given anastrozole alone. She also gives an update on bisphosphonates and osteonecrosis of the jaw at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Dr. Gralow is a Professor, Medical Oncology, Department of Medicine, at the University of Washington School of Medicine. She is the Director of Breast Medical Oncology at Seattle Cancer Care Alliance and Member of the Fred Hutchinson Cancer Research Center, Clinical Research Division.
Shared By : vitaloptions
Posted on : 01/12/12
Added : 7 years ago